Jamshedpur Reporter

Acromegaly: Overview, Epidemiology, Market, Emerging Drugs and Key players

 Breaking News
  • No posts were found

Acromegaly: Overview, Epidemiology, Market, Emerging Drugs and Key players

January 27
13:35 2021
Acromegaly: Overview, Epidemiology, Market, Emerging Drugs and Key players

DelveInsight Business Research LLP
DelveInsight’s ‘Acromegaly Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the Acromegaly, historical and forecasted epidemiology as well as the Acromegaly market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Acromegaly is a rare and chronic disorder characterized by excess growth hormone secretion and elevated insulin-like growth factor-1 levels, most often caused by a pituitary Adenoma.

 

How Acromegaly has impacted people’s lives?

Acromegaly Epidemiology Insights

  • The total Acromegaly prevalent cases in 2017 were 64,508
  • The diagnosed patient pool cases of Acromegaly in 2017 was 49,814 
  • The prevalent population of Acromegaly in the United States in 2017 was 28,671 
  • Acromegaly prevalent cases in Japan in 2017 was 10,690
  • EU5 countries occupied around 38.98% of Acromegalypatient pool amongst 7MM in 2017

 

How will Disease transform Acromegaly Market? 

Acromegaly market size in 7MM in 2017 was USD 956.96 Million

Acromegaly Market Drivers

  • Robust pipeline
  • Increase in Prevalence
  • More efficacious mono and combination therapies

Acromegaly Market Barriers

  • Economic burden
  • Low disease awareness and delay in diagnosis
  • No standard cure available

 

Which biotechnical companies are developing Acromegaly drugs? 

The emerging therapies for Acromegalytreatment that are expected to launch in the forecasted period (2020–2030) include Octreotide Capsules (Chiasma Pharma), IONIS-GHR-LRx (Ionis Pharmaceuticals), ATL1103 (Antisense Therapeutics), CAM2029 (Camurus), Veldoreotide (Strongbridge Biopharma), CRN00808 (Crinetics Pharmaceuticals), and Lanreotide PRF (Ipsen).

 

 

Media Contact
Company Name: DelveInsight
Contact Person: DelveInsight
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/